Cooper Companies (NASDAQ:COO) Price Target Raised to $125.00

Cooper Companies (NASDAQ:COO) had its target price boosted by Robert W. Baird from $118.00 to $125.00 in a research report report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the medical device company’s stock.

Other equities analysts also recently issued reports about the stock. Jefferies Financial Group raised shares of Cooper Companies from a hold rating to a buy rating and lifted their price target for the company from $107.00 to $115.00 in a report on Tuesday, July 16th. Piper Sandler increased their price target on Cooper Companies from $115.00 to $120.00 and gave the stock an overweight rating in a research report on Thursday. Wells Fargo & Company boosted their price objective on Cooper Companies from $110.00 to $115.00 and gave the stock an overweight rating in a research note on Thursday. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Cooper Companies in a report on Friday, August 23rd. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies presently has an average rating of Moderate Buy and an average price target of $113.61.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $105.73 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.95 and a debt-to-equity ratio of 0.34. The business has a 50 day moving average price of $91.53 and a 200 day moving average price of $94.21. The company has a market cap of $21.05 billion, a price-to-earnings ratio of 62.19, a PEG ratio of 2.34 and a beta of 0.98. Cooper Companies has a twelve month low of $75.93 and a twelve month high of $106.95.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a return on equity of 8.87% and a net margin of 9.11%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.84 EPS. Research analysts predict that Cooper Companies will post 3.57 earnings per share for the current year.

Hedge Funds Weigh In On Cooper Companies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. increased its stake in Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 174 shares in the last quarter. Innealta Capital LLC bought a new stake in shares of Cooper Companies in the 2nd quarter valued at $25,000. Covestor Ltd raised its stake in Cooper Companies by 305.9% during the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after buying an additional 208 shares during the period. Crewe Advisors LLC lifted its holdings in Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after acquiring an additional 252 shares in the last quarter. Finally, Global Retirement Partners LLC grew its stake in Cooper Companies by 358.6% in the first quarter. Global Retirement Partners LLC now owns 321 shares of the medical device company’s stock valued at $33,000 after acquiring an additional 251 shares during the period. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.